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Irritable bowel syndrome (IBS) is a chronic functional gastro-
intestinal disorder characterized by episodic abdominal pain 
or discomfort in association with altered bowel habits (diar-
rhea and/or constipation). Other gastrointestinal symptoms, 
such as bloating and ﬂ  atulence, are also common. A variety 
of factors are believed to play a role in the development 
of IBS symptoms, including altered bowel motility, visceral 
hypersensitivity, psychosocial stressors, altered brain-gut 
interactions, immune activation/low grade inflammation, 
alterations in the gut microbiome, and genetic factors. In the 
absence of biomarkers that can distinguish between IBS 
subgroups on the basis of pathophysiology, treatment of this 
condition is predicated upon a patient’s most bothersome 
symptoms. In clinical trials, effective therapies have only of-
fered a therapeutic gain over placebos of 7-15%. Evidence 
based therapies for the global symptoms of constipation pre-
dominant IBS (IBS-C) include lubiprostone and tegaserod; ev-
idence based therapies for the global symptoms of diarrhea 
predominant IBS (IBS-D) include the probiotic Bifidobacter 
infantis, the nonabsorbable antibiotic rifaximin, and alos-
etron. Additionally, there is persuasive evidence to suggest 
that selected antispasmodics and antidepressants are of 
beneﬁ  t for the treatment of abdominal pain in IBS patients. 
Finally, several emerging therapies with novel mechanisms 
of action are in development. Complementary and alterna-
tive medicine therapies including probiotics, herbal therapies 
and acupuncture are gaining popularity among IBS sufferers, 
although concerns regarding manufacturing standards and 
the paucity of high quality efﬁ  cacy and safety data remain. 
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INTRODUCTION
The irritable bowel syndrome (IBS) is a chronic functional 
gastrointestinal (GI) disorder characterized by the presence of 
episodic abdominal pain or discomfort in association with al-
tered bowel habits (diarrhea and/or constipation) and other GI 
symptoms such as bloating and flatulence. By definition, these 
symptoms should be occurring in the absence of identifiable 
structural or biochemical abnormalities.
1 
IBS is the most common diagnosis rendered by gastroen-
terologists affecting 10-20% of the US adult population.
2 Data 
on the prevalence of IBS based upon geographic region can be 
found in Table 1. Though IBS affects both men and women and 
any age group, IBS is more commonly diagnosed in women and 
younger individuals.
3,4 The burden of illness associated with IBS, 
in terms of quality of life, work productivity and health resource 
utilization, is considerable.
5,6
PATHOPHYSIOLOGY OF IBS
It is likely that IBS, the diagnosis of which is currently predi-
cated exclusively upon the presence of characteristic symptoms, 
is comprised of a number of different disease states for which 
we currently lack reliable biomarkers. A variety of factors are 
believed to play a role in the development of the IBS symptoms 
including altered bowel motility, visceral hypersensitivity, psy-
chosocial stressors, altered brain-gut interactions, low grade in-
flammation, alterations in the gut microbiome, and genetic fac-
tors.
7-10 A leading hypothesis holds that an interaction of one or 
more of these etiologic factors is responsible for the frequently 
complex and heterogeneous symptoms of IBS.
Alterations in rectal, colonic and small bowel motility have 
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symptoms in some patients. A number of studies have reported 
accelerated small bowel and colon transit as well as exagger-
ated bowel motility patterns in those with diarrhea predominant 
IBS (IBS-D).
11-14 Likewise, several studies have report delayed 
bowel transit in those with constipation predominant IBS (IBS-
C).
11,13 Visceral hypersensitivity to mechanical distension can 
often be identified in IBS patients.
15-18 Unfortunately, visceral 
hypersensitivity does not occur commonly enough to be con-
sidered a biomarker of IBS.
19 There is recent evidence to suggest 
central dysregulation of emotional arousal and pain modula-
tion in IBS.
20,21 Psychological distress is not only a common co-
morbidity in IBS patients, but also a factor which amplifies IBS 
symptoms and perhaps plays a direct role in the pathogenesis 
of IBS.
22,23 Alterations in a key neurotransmitters such as sero-
tonin, which play a role in sensation, secretion, absorption and 
motility of the GI tract have been identified in IBS patients.
24 A 
number of studies have reported increased serotonergic activity 
in IBS-D and decreased serotonergic activity in IBS-C.
25-27 Post-
infectious IBS (PI-IBS) which as the name implies occurs fol-
lowing an infectious gastroenteritis, is a well established entity 
believed to arise from deranged immune activation leading to 
persistent low grade inflammation and alterations in the gut 
microbiome.
28 PI-IBS has been reported following a variety of 
acute infections including bacteria, viruses and parasites.
29-31 
Recent studies suggest that some individuals are genetically pre-
disposed to developing PI-IBS, with individuals demonstrating 
an increased pro-inflammatory and/or decreased anti-inflam-
matory cytokine response to infection.
32,33 There is a growing 
body of evidence to suggest that alterations in the microbiome 
may play a role in the development of IBS symptoms. The 
greatest attention has been placed on the possible role of small 
intestinal bacterial overgrowth (SIBO) in the pathogenesis of IBS 
symptoms, particularly bloating and diarrhea.
34,35 Further, early 
studies utilizing gene cloning and sequencing techniques as well 
as polymerase chain reaction have demonstrated differences 
in the microbiome in IBS patients when compared to healthy 
controls.
36,37 More recent studies have combined sophisticated 
molecular techniques with more traditional culture to associate 
specific bacterial strains with the symptoms of IBS-D.
38,39 The 
role of genetic factors in the development of IBS has grown 
from early familial aggregation studies
40 to more recent reports 
concerning genetic polymorphisms involving genes targeting 
proinflammatory cytokines, the serotonin reuptake transporter, 
tryptophan hydroxylase, sodium ion channel proteins and the 
alpha 2A adrenergic receptor. 
An interesting clinical observation which might have im-
plications with regard to pathogenesis is the frequent overlap 
between IBS symptoms and other GI and non-GI symptoms. For 
example, Nastaskin et al.
41 conducted a systematic review which 
suggested a strong overlap between IBS and gastroesophageal 
reflux disease that exceeds the expected individual presence of 
each condition. Recently, Ford et al.
42 reported the results from a 
systematic review that reported an 8-fold increase in prevalence 
of IBS amongst people with dyspepsia compared to the general 
population. Although some have reported that overlapping up-
per and lower GI symptoms tend to occur more commonly in 
individuals with anxiety,
43 the mechanistic explanation which 
underlies this phenomenon remains unclear. It is attractive to 
speculate that patients with diffuse upper and lower GI symp-
toms hallmarked by pain or discomfort may have a centrally 
driven abnormality in pain processing or perception. There is 
data to suggest that patients with overlapping GI symptoms 
have more severe/frequent GI symptoms and worse health re-
lated quality of life.
44-46 
CURRENT AND EMERGING MEDICAL THERAPIES FOR 
IBS
In the absence of biomarkers which can distinguish between 
IBS subgroups on the basis of pathophysiology, treatment of 
this condition is predicated upon the patient’s most bothersome 
symptoms. Though there is some overlap in the therapies of-
fered to the different IBS subgroups, treatment decisions are 
largely based upon the frequency and severity of constipation, 
diarrhea, bloating or pain. The American College of Gastroenter-
ology (ACG) recently published an evidence-based monograph 
on therapies for IBS.
47 A summary of the criteria used in this 
monograph to judge the therapies for IBS is provided in Table 
2. Summaries of the recommendations from this monograph for 
IBS-C and IBS-D can be found in Tables 3 and 4.
IBS-C
1. Fiber supplements
Dietary fiber supplements consist of non-digestible carbo-
hydrates that increase stool bulk and water content resulting 
Table 1. Epidemiologic Data for IBS by Geographic Region
Location Prevalence (%) % IBS subtype (C:D:A) Gender (F:M)
North America
134 17-20* 27.1-29.4:27.1-33.9:26.3
135-137 1:1–2:1
European Union
138 4
̈ 16:21:63 2:1
Asia
139,140 2.9-15.6 No systematic evaluation has been reported 1:1–1.5:1
IBS, irritable bowel syndrome.
*Manning criteria; 
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in decreased stool consistency and increased stool frequency.
48 
Commercially available fiber supplements include psyllium, 
ispaghula husk, bran (wheat and corn), methylcellulose, calcium 
polycarbophil, and partially hydrolyzed guar gum (PHGG). An 
evidence-based systematic review on the effectiveness of fiber 
supplements in the management of IBS conducted by the ACG 
IBS task force concluded that psyllium hydrophilic mucilliod 
(ispaghula husk) is moderately effective in the treatment of IBS 
(Grade 2C, Table 1).
47 The task force added that wheat bran or 
corn bran is no more effective than placebo in relief of the glob-
al IBS symptoms. A recent randomized, controlled trial corrobo-
rated these results.
49 Collectively, the data suggest that psyllium 
may improve constipation symptoms such as stool frequency 
and consistency in patients with IBS-C and perhaps mixed type 
IBS (IBS-M). Bran does not appear to offer symptomatic ben-
efit and the effect of other available fiber supplements remains 
largely unknown. Potential adverse effects of fiber supplements 
may include bloating, abdominal distention and flatulence.
2. Laxatives
Laxatives are commonly used as a treatment for patients with 
IBS-C. In addition, some IBS-M patients report extended peri-
ods with small, hard bowel movements or no bowel movement 
followed by periods with loose stools. Such patients are often 
constipated and may benefit from laxative therapies. Traditional 
laxative therapies include osmotic agents, stimulants, and stool 
softeners. Only the osmotic laxative, polyethylene glycol (PEG), 
has been assessed in a randomized trial which enrolled 28 post-
pubertal adolescent IBS-C patients.
50 Patients were randomized 
to receive 4 weeks of PEG or PEG and the 5-HT4 agonist, tegas-
erod. In the group that received PEG alone, there was a signifi-
cant increase in mean bowel movement frequency compared 
to baseline (2.07 to 5.04 weekly bowel movements, p<0.05) but 
no change in abdominal pain. The group that received both 
Table 2. Grading Recommendations from the ACG Evidence-Based IBS Monograph
47
Grade of 
recommendation/
description
Benefit vs risk and burdens
Methodological quality of 
supporting evidence
Implications
1A. Strong recommendation, 
high-quality evidence
Benefits clearly outweigh 
risk and burdens, or vice 
versa
RCTs without important limitations 
or overwhelming evidence from 
observational studies
Strong recommendation, can apply to most 
patients in most circumstances. Further 
evidence is unlikely to change the level of 
confidence in the estimate of effect
1B. Strong recommendation, 
moderate-quality evidence
Benefits clearly outweigh 
risk and burdens, or vice 
versa
RCTs with important limitations 
(inconsistent results, method-
ological flaws, indirect, or impre-
cise) or exceptionally strong evi-
dence from observational studies
Strong recommendation, can apply to most 
patients in most circumstances. Higher 
quality evidence may change the level of 
confidence in the estimate of effect
1C. Strong recommendation, 
low-quality or very low-
quality evidence
Benefits clearly outweigh 
risks and burdens, or 
vice versa
Observational studies or case series Strong recommendation can apply to most 
patients in most circumstances. Higher 
quality evidence is very likely to change the 
level of confidence in the estimate of effect
2A. Weak recommendation, 
high-quality evidence
Benefits closely balanced 
with risks and burdens
RCTs without important limitations 
or overwhelming evidence from 
observational studies
Weak recommendation, best action may dif-
fer depending on circumstances or patients’ 
or societal values. Further evidence is un-
likely to change the level of confidence in 
the estimate of effect
2B. Weak recommendation, 
moderate-quality evidence
Benefits closely balanced 
with risks and burdens
RCTs with important limitations 
(inconsistent results, method-
ological flaws, indirect, or impre-
cise) or exceptionally strong evi-
dence from observational studies
Weak recommendation, best action may dif-
fer depending on circumstances or patients’ 
or societal values. Higher quality evidence 
may well change evidence the level of con-
fidence in the estimate of effect
2C. Weak recommendation, 
low-quality or very low-
quality evidence
Uncertainty in the esti-
mates of benefits, risks, 
and burden; benefits, 
risk, and burden may be 
closely balanced
Observational studies or case series Very weak recommendation; other alterna-
tives may be equally reasonable. Higher 
quality evidence is likely to change the level 
of confidence in the estimate of effect
ACG, American College of Gastroenterology; IBS, irritable bowel syndrome; RCT, randomized controlled trial.256  Gut and Liver, Vol. 5, No. 3, September 2011
PEG and tegaserod enjoyed improvements in bowel movement 
frequency and pain (p<0.05). Other commonly used laxative 
therapies have thus far, not been adequately studied as a treat-
ment for IBS-C. Though further studies assessing the efficacy 
of laxative therapies for IBS-C are clearly needed, the relative 
safety, availability, and low cost of these drugs make their con-
tinued use as a treatment for constipation related complaints in 
IBS patients quite likely. 
3. Prokinetic agents
 Prokinetics are a diverse group of compounds which exert 
effects on GI motility, secretion, and sensation. Most prokinetic 
agents which have been developed for the treatment of IBS 
have focused on serotonin. Of the 14 different serotonin recep-
tor subtypes which have been identified, 5-HT1p, 5-HT3 and 
5-HT4 receptors have the greatest evidence supporting a role in 
GI and colonic function and sensation. In the GI tract, 5-HT4 
receptors are found on enteric neurons and smooth muscle cells. 
Stimulation of 5-HT4 receptors leads to acetylcholine release 
and prokinetic effects.
51,52 A number of 5-HT4 agonists have 
been developed as potential treatments for patients with IBS-C. 
Tegaserod is a selective 5-HT4 receptor partial agonist which 
has been found to be more effective than placebo for global 
IBS symptoms as well as abdominal pain and constipation in 
multiple short- and long-term studies of women with IBS-C and 
IBS-M from around the world.
53-59 In 2007, a review of the clini-
cal trials database by the manufacturer revealed an increased 
incidence of cardiovascular and cerebrovascular events in the 
tegaserod treatment group compared to the placebo group. This 
analysis specifically revealed a total of 13 cardiovascular isch-
emic events (3 myocardial infarctions, 1 sudden cardiac death, 
6 cases of unstable angina and 3 cerebrovascular accidents) in 
11,614 patients treated with tegaserod compared with 1 event 
in the 7,031 patients receiving placebo.
60 Although the event 
rates were quite low (0.1% in the tegaserod group vs 0.01% in 
the placebo group) the difference was found to be statistically 
significant (p=0.02). The significance and explanation for this 
discrepancy remains poorly characterized, although there has 
been speculation that tegaserod may induce platelet aggrega-
tion via 5-HT4 receptors on platelets.
61 Related to these findings, 
tegaserod was withdrawn in the many countries, including the 
US and Canada in 2009. Tegaserod remains available in a small 
number of countries throughout the world. The most commonly 
reported side effects included diarrhea, headache and abdominal 
Table 4. Evidence-Based Summary of Medical Therapies for IBS-D Symptoms
Improvements in symptoms
Grade* Global 
symptoms
Pain Bloating
Stool 
frequency
Stool 
consistency
Alosetron + + + + 2A/1B
Antibiotics (rifaximin) + + 1B*
Antidepressants + + 1B
Loperamide ++ 2 C
Antispasmodics ± + 2C
Probiotics (Bifidobacteria/some combos) + 2C
Fiber (psyllium) Insufficient evidence
Adapted from Am J Gastroenterol 2009;104 Suppl 1:S1-S35.
47
IBS-D, diarrhea predominant irritable bowel syndrome.
*Positive results from 2 large phase 3 studies published since creation of the ACG document. 
Table 3. Evidence-Based Summary of Medical Therapies for IBS-C Symptoms
Improvements in symptoms
Grade
Global symptoms Pain Bloating Stool frequency Stool consistency
Lubiprostone + + + 1B
Antidepressants + + 1B
Tegaserod* + ± + + + 2A
Fiber (psyllium) + + 2C
Laxatives (PEG) + 2C
Adapted from Am J Gastroenterol 2009;104 Suppl 1:S1-S35.
47
IBS-C, constipation predominant irritable bowel syndrome; PEG, polyethylene glycol.
*Available in the US only under Emergency IND program.Chey WD, et al: Pharmacologic and Complementary and Alternative Medicine Therapies for Irritable Bowel Syndrome  257
pain. Twenty-six cases of possible colonic ischemia were also 
reported during post-marketing surveillance providing an esti-
mated incidence of 7-8 cases of colonic ischemia per 100,000 
patient-years of tegaserod use.
62
It is reasonable to hypothesize that other 5-HT4 agonists such 
as mosapride and prucalopride might offer benefits for IBS-C 
patients, though to date, this has not been convincingly dem-
onstrated in high quality randomized trials. Pumosetrag is a po-
tent, partial 5-HT3 agonist with prokinetic effects in animals and 
humans. Work is proceeding in the development of pumosetrag 
as a treatment for IBS-C. Itopride is a dopaminergic antagonist 
and cholinesterase inhibitor which exerts effects on upper and 
lower GI motility and transit in animals. Randomized, placebo 
controlled trials evaluating itopride in patients with IBS-C are 
not yet available.
63 
4. Prosecretory agents
In recent years, a number of agents have been developed 
which increase intestinal secretion and in this way improve 
symptoms in patients with IBS-C. Lubiprostone, a chloride type 
2 channel activator, is the first such drug to have been approved 
for the treatment of patients with IBS-C in the US. The efficacy 
and tolerability of lubiprostone in IBS-C has been assessed in 
several high quality randomized controlled trials (RCTs). A phase 
2, dose-ranging, double-blind, placebo controlled trial was per-
formed in 194 adults with IBS-C (92% female, 83% Caucasian).
64 
In this study, lubiprostone was superior to placebo with regard 
to spontaneous bowel movement frequency, stool consistency, 
straining, constipation severity, bloating and abdominal pain. 
Two subsequent phase 3 multicenter, double-blind, random-
ized, placebo-controlled trials further evaluated lubiprostone 8 
mcg twice daily in 1,167 patients (92% female) with IBS-C.
65 
Using a highly rigorous multi-dimensional responder definition 
designed to minimize the placebo effect, those on lubiprostone 
were significantly more likely to be responders as those on 
placebo (18% vs 10%). Further, lubiprostone was significantly 
more likely than placebo to improve individual IBS symptoms 
including abdominal pain, stool consistency, straining, consti-
pation severity and quality of life. After a careful review of the 
literature, the ACG IBS task force concluded that lubiprostone 
at a dose of 8 mcg twice daily was more effective than placebo 
in relieving global IBS symptoms in women with IBS-C (Grade 
1B).
47 The task force commented on the lack of data addressing 
the efficacy of lubiprostone in men with IBS-C. Lubiprostone 8 
mcg twice daily dosed with food was found to be generally well 
tolerated. The most common side effects at this dose included 
nausea (8%) and diarrhea (6%). Five percent of IBS-C patients 
enrolled in the phase III trials withdrew related to side effects. 
There have been postmarketing reports of dyspnea in a small 
number of patients prescribed lubiprostone. Lubiprostone is also 
contraindicated in pregnancy due to fetal demise in guinea pig 
studies. 
Guanylate cyclase-C (GC-C) agonists are another class of 
prosecretory agents which are being developed for IBS-C. Bind-
ing of intestinal GC-C receptors stimulates production of cyclic 
guanosine monophosphate (cGMP) which activates the cystic 
fibrosis transmembrane conductance regulator (CFTR) channel 
leading to intestinal chloride secretion. Linaclotide is a locally 
acting synthetic 14-amino acid peptide which avidly binds GC-C 
receptors. Linaclotide has been shown to improve symptoms in 
patients with chronic constipation.
66,67 The most common side 
effect reported with linaclotide has been diarrhea which in most 
cases has been mild to moderate in severity and self limited in 
duration. More recently, two phase III randomized, controlled 
trials which enrolled over 1,600 patients with IBS-C found lina-
clotide 266 μg was superior to placebo for constipation-related 
complaints and abdominal pain for up to 26 weeks.
68
Plecanatide is another orally administered GC-C agonist. A 
recently completed phase IIa study reported that oral plecana-
tide given at doses of 0.3, 1.0, 3.0, and 9.0 mg once daily for 14 
days improved stool frequency, straining, and abdominal dis-
comfort in patients with chronic constipation. Plecanatide treat-
ment led to no diarrhea and no severe adverse events.
69 To date, 
there are no data on the efficacy of plecanatide in IBS patients.
5. Bile acid modulators
Bile acids can alter intestinal and colonic motility and secre-
tion. Recent work has utilized specific bile acid analogs or drugs 
which alter bile acid reabsorption as novel therapies for IBS-C. 
The main results from a trial which evaluated the effects of che-
nodeoxycholic acid (CDCA) on colonic transit and clinical pa-
rameters in female IBS-C patients were recently reported. CDCA 
significantly accelerated overall colonic transit and improved 
clinical outcomes including stool frequency, stool consistency 
and facilitated the passage of stool. The most common side ef-
fect with CDCA was abdominal cramping/pain which was re-
ported by over 40% of patients vs none with placebo.
70 
A3309 is a novel small molecule which inhibits ileal bile acid 
transporters. In so doing, A3309 results in greater delivery of 
bile acids to the right colon with consequent effects on motil-
ity, transit and secretion. A3309 has been shown to accelerate 
colon transit in animals and humans.
63 Top line data from a 
randomized, placebo-controlled phase IIb dose range study in 
190 patients with chronic constipation were recently reported. 
A3309 once daily at doses of 5, 10, and 15 mg/day showed dose 
dependent effects on the primary outcome of weekly spontane-
ous bowel movements as well as a number of other constipation 
related secondary outcomes. A3309 failed to show significant 
effects on abdominal pain in this trial but results may have been 
confounded by low baseline levels of abdominal pain. The most 
common side effect with A3309 was dose dependent diarrhea.
71 
Studies of A3309 in IBS-C patients are not yet available. 258  Gut and Liver, Vol. 5, No. 3, September 2011
IBS-D
1. Antidiarrheals
Antidiarrheals are perhaps the most commonly employed 
agents used in the treatment of IBS-D. Only loperamide has 
been evaluated in RCTs for the treatment of IBS.
72-75 Although 
limited by significant methodological flaws, in aggregate these 
studies demonstrate improvements in stool consistency, stool 
form and urgency amongst IBS-D patients. The effect of loper-
amide on abdominal pain has been less consistent. The system-
atic review conducted ACG IBS task force concluded that loper-
amide was helpful for diarrhea related symptoms such as stool 
frequency and consistency but no more effective than placebo 
at reducing abdominal pain, bloating or global symptoms in IBS 
patients. The task force added that safety and tolerability data 
on loperamide remains lacking.
47 One advantage of loperamide 
is its peripheral site of action with little penetration of the blood 
brain barrier and thus, little potential for CNS side effects or ha-
bituation. 
2. Serotonergic agents
5-HT3 receptor antagonists slow small bowel transit, de-
crease intestinal secretion, decrease colonic tone, and delay 
colonic transit.
76-79 The best studied 5-HT3 receptor antagonist 
in patients with IBS-D is alosetron. Methodologically rigorous, 
large clinical trials have consistently demonstrated the efficacy 
of alosetron in relieving IBS symptoms including abdominal 
pain, diarrhea, and urgency. Alosetron has also been shown to 
improve quality of life in women with IBC-D and IBS-M.
80-83 
The long-term efficacy and safety of alosetron has also been es-
tablished in a 48-week placebo-controlled trial.
84 Alosetron has 
been assessed in 662 men with IBS-D demonstrating superiority 
to placebo in providing adequate relief of abdominal pain (53% 
vs 40%, p=0.04) and improving stool consistency (p<0.001).
85 
Due to potential serious side effects including severe constipa-
tion and ischemic colitis,
86 alosetron is currently prescribed in 
the US through a risk management plan, the details of which 
can be found in the product label. A recent systematic review 
and meta-analysis conducted by the ACG IBS task force con-
cluded that alosetron was more effective than placebo at reliev-
ing global IBS in men with IBS-D (Grade 2B) and women with 
IBS-D (Grade 2A). The task force went on to say that the bene-
fits and harms of alosetron were most favorable in women with 
severe IBS-D who have not responded to conventional medical 
therapies (Grade 1B).
47,87
Ramosetron is another 5-HT3 receptor antagonist which has 
recently been evaluated in a double-blind, placebo-controlled 
Phase II trial in 418 patients with IBS-D from Japan. In this 
trial, female and male patients with IBS-D were randomized to 
ramosetron at doses of 1, 5, and 10 μg or placebo given once 
Fig. 1. Emerging pharmacological therapies for IBS and mechanisms of action. Blue boxes represent drugs used for IBS-D; Pink boxes represent 
drugs used for IBS-C; Purple boxes represent drugs used for both IBS subtypes. Adapted from Gastroenterol Clin North Am 2011;40:223-43.
63
IBS, irritable bowel syndrome; κ-Opioid, kappa opioid; GI, gastrointestinal; GC-C, guanylate cyclase; CFTR, cystic fibrosis transmembrane con-
ductance regulator; CRF-1R, corticotropin releasing factor receptor type1; IBAT, ileal bile acid transporter; CTT, colonic transit time; MI, motility 
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daily for 12 weeks.
88 Patients randomized to ramosetron 5 and 
10 μg had significantly higher global responder rates than 
placebo (42.57% and 43.01% vs 26.92%, p=0.027, p=0.026, 
respectively). Ramosetron also led to significantly greater im-
provements in relief of abdominal discomfort and/or pain and 
abnormal bowel habits. Dose-dependent constipation and hard 
stools were noted but no cases of ischemic colitis or serious 
complications of constipation were reported. Ramosetron is ap-
proved for use in Japan but is not available in US.
Emerging pharmacological therapies for IBS and mechanisms 
of action are summarized in Fig. 1.
3. Antibiotics
There is now robust data to suggest that treatment with a 
course of oral antibiotics improves IBS symptoms in the short 
term.
89-91 The largest and most rigorously designed studies ad-
dressing this issue have utilized the non-absorbable antibiotic 
rifaximin.
90-92 Rifaximin is a derivative of rifamycin which is 
concentrated in the gut lumen with little systemic absorption. 
This feature makes rifaximin an attractive candidate for the 
modification of the gut flora as it mitigates some of the concerns 
regarding resistance and side effects that are more relevant with 
systemically absorbed antibiotics. Data from two phase 3 trials 
in 1,260 non-constipation IBS patients demonstrated that rifaxi-
min 550 mg three times daily for 14 days significantly improved 
global symptoms, as well as individual symptoms including 
bloating, abdominal pain and stool consistency compared to 
placebo in a subset of affected patients for up to 3 months. It is 
quite interesting that a short course of therapy results in clinical 
benefits which persist well beyond the discontinuation of the 
antibiotic. It remains unclear whether these clinical benefits are 
the result of reduction/modification of intestinal or colonic flora 
or both. Though the precise mechanism of action remains to be 
determined, the authors of this study proposed several potential 
explanations for these findings: 1) the effect of rifaximin, by 
affecting gut bacteria, could reduce the bacterial products that 
negatively affect the host; 2) the effect on gut flora might alter 
local mucosal engagement of bacteria such as the immune re-
sponses of the host or; 3) the antibiotic alters both the bacteria 
and host responses. The safety profile during and after treatment 
with rifaximin was comparable to that observed with placebo. 
There were no cases of C. difficile associated diarrhea or isch-
emic colitis reported in the phase 3 trials.
91 Despite these very 
encouraging results, a number of important questions remain 
regarding the role of antibiotic therapy in IBS patients.
93 Clini-
cal wisdom and some data suggest that an unclear proportion 
of rifaximin responders will develop recurrent IBS symptoms 
over time.
94 Neither the proportion of patients who will relapse 
or the duration of clinical response beyond 10 weeks of therapy 
is currently known. Further, the optimal management strategy 
for patients who experience symptom relapse is also unknown 
at present. Studies to clarify these questions are currently being 
developed and will clarify the optimal means by which to utilize 
antibiotic therapy in IBS patients. 
4. Other emerging therapies for IBS-D
A number of other compounds with a variety of mechanisms 
of action are in various stages of development for patients with 
IBS-D.
63 Some examples include kappa opioid agonists such as 
asimadoline,
95,96 orally administered, non-absorbable, carbon-
based adsorbent such as AST-120,
97 corticotropin releasing fac-
tor (CRF) antagonists such as pexacerfont and GW876008,
98,99 
chloride secretion inhibitors such as crofelemer,
100 and atypical 
benzodiazepines such as detofisopam,
101 and tryptophan hy-
droxylase inhibitors such as LX-1031.
102
ABDOMINAL PAIN/DISCOMFORT
1. Antispasmodics
Antispasmodics remain a mainstay of therapy for IBS. Anti-
spasmodics encompass a diverse group of drug classes including 
antimuscarinics, smooth muscle relaxants, anticholinergics and 
unique agents such as pinaverium, an ammonium derivative 
with calcium channel blocking properties, and trimebutine, a 
peripheral opiate agonist.
103 Although antispasmodics remain 
among the most commonly prescribed drugs for IBS, the clinical 
evidence supporting their use is limited. Given the lack of high 
quality studies addressing the efficacy of specific antispasmodic 
agents in IBS, this drug class has been largely assessed through 
systematic reviews and meta-analyses.
47,104-106 The ACG IBS task 
force recently performed a comprehensive evidence-based sys-
tematic review and meta-analysis which concluded that the an-
tispasmodics hyoscine, cimetropium, and pinaverium provided 
short-term relief of abdominal pain/discomfort in IBS patients.
47 
The task force added that evidence for long-term efficacy, safety 
and tolerability was limited. The available evidence and clini-
cal experience suggest that antispasmodics are most effective in 
IBS patients with crampy abdominal pain and diarrhea. Clinical 
wisdom (non-evidence based) suggests that antispasmodics are 
most effective in patients with intermittent, meal related symp-
toms. Patients with continuous pain rarely improve with this 
form of therapy. The anticholinergic properties of these agents 
can be associated with the development of significant side ef-
fects including dry mouth, dizziness, blurry vision, confusion 
(particularly in the elderly), urinary retention and constipation. 
The use of these agents should be avoided in the elderly.
107 
2. Psychotropic agents
The three major classes of psychotropic agents employed in 
the treatment of IBS include tricyclic antidepressants (TCAs), 
selective serotonin reuptake inhibitors (SSRIs), and serotonin-
norepinephrine reuptake inhibitors (SNRIs). Psychotropics pos-
sess a variety of peripheral and central effects which make them 
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modulation of pain perception, mood stabilization, treatment 
of coexistent psychiatric disorders, and possible direct effects 
on GI motility and secretion. Indeed recent systematic reviews 
and meta-analyses have found these agents to be more effective 
than placebo in the treatment of overall symptoms and abdomi-
nal pain in IBS patients.
108,109 On the other hand, the effects of 
psychotropic agents on bowel symptoms in IBS patients have 
been less robust and less consistent than the benefits reported 
for global symptoms and abdominal pain/discomfort. 
TCAs are the best studied class of psychotropic agents in the 
treatment of IBS. In a recent systematic review by the ACG IBS 
task force, the pooled data from 9 RCTs totaling 575 patients 
demonstrated the superiority of TCAs over placebo in the treat-
ment of IBS with a number needed to treat (NNT) of 4.
47 The 
most common side effects of TCAs result from their anticho-
linergic properties, including constipation, tachycardia, urinary 
retention, and xerostomia. Patients may also encounter central 
side effects including insomnia, agitation, and nightmares. The 
secondary amine TCAs (desipramine, nortriptyline) tend to be 
better tolerated than tertiary amine TCAs (amitriptyline, imip-
ramine) given their decreased anticholinergic properties. Based 
upon the available evidence, it seems reasonable to conclude 
that TCAs are more effective than placebo in relieving global 
symptoms and abdominal pain in IBS. Given the potential for 
side effects, TCAs are most appropriate for IBS patients with 
persistent, moderate to severe symptoms predominated by ab-
dominal pain and loose stools. To minimize side effects, TCAs 
should be started at a low dose (10-25 mg) and slowly titrated 
up as needed to achieve symptom control. 
Given the important peripheral and central roles of serotonin 
in gut function and sensation, there has been growing interest 
in the use of SSRIs for IBS. As a treatment for IBS, SSRIs offer 
potential advantages over TCAs including anxiolytic effects and 
arguably, a more favorable side effect profile. In the systematic 
review and meta-analysis conducted by the ACG IBS task force, 
pooled data from 5 RCTs totaling 230 patients demonstrated 
the superiority of SSRIs over placebo in the treatment of IBS 
with an NNT of 3.5.
47 The task force concluded that SSRIs were 
more effective than placebo in relieving global symptoms and 
abdominal pain in IBS, although limited data exists regarding 
their safety and tolerability. In contrast to TCAs, SSRIs are likely 
to increase small bowel and colonic transit.
110 Therefore, it has 
been argued that SSRIs might be better suited for patients with 
IBS-C. From the limited evidence available, it seems reasonable 
to conclude that SSRIs may offer benefits in IBS subtypes with a 
tendency toward constipation and those with coexistent anxiety 
disorders. 
The unique dual effect of SNRIs on serotonin and norepi-
nephrine has made this class of psychotropic agents attractive 
for potential use in IBS. At the present time, use of these agents 
is largely based upon evidence from small observational or 
translational studies. There is a single open-label study assess-
ing the efficacy of duloxetine in 15 adults with IBS.
111 Although 
duloxetine was associated with significant improvements in 
abdominal pain, loose stools, anxiety and quality of life; nearly 
50% dropped out of the study due to side effects. Venlafaxine 
has been shown to increase colonic compliance, decrease co-
lonic tone and reduce sensation of colonic distention in healthy 
adults.
112 Large, methodologically rigorous, randomized trials to 
elucidate the clinical benefits and tolerability of SNRIs in IBS 
patients are eagerly awaited. 
COMPLEMENTARY AND ALTERNATIVE MEDICINE THER-
APIES
The term “complementary and alternative medicine” (CAM) 
refers to treatment practices which are not currently considered 
an integral part of conventional allopathic medical practice. 
Treatments are considered as “complementary” when used in 
addition to conventional therapies and as “alternative” when 
used instead of conventional therapies.
74 A number of factors 
are likely fueling the increasing interest in CAM therapies for 
IBS. First, traditional medical therapies for IBS offer marginal 
efficacy with therapeutic gains over placebo of 7-15%. Further, 
in many countries including the US, prescription medication 
insurance coverage for IBS and other “quality of life” condi-
tions is decreasing. Finally, perhaps related to concerns regard-
ing the safety of prescription medications, there appears to be a 
growing desire amongst patients for more holistic and “natural” 
treatment options. A population based survey in 1,409 subjects 
from the UK indicated that over 50% of IBS patients used CAM 
treatments
113 while another prospective 6-month study from a 
large HMO in the US found that 35% of patients with functional 
GI diseases use CAM.
114 The following section will focus on the 
evidence addressing the efficacy of CAM therapies for IBS.
1. Probiotics
Probiotics are live microorganisms which when taken in suf-
ficient quantities, confer a health benefit. Probiotics are distin-
guished from prebiotics (substrates which encourage the growth 
of probiotic organisms), synbiotics (a combination of a prebiotic 
and probiotic), or postbiotics (isolated bacterial components). 
Probiotics may offer benefits to IBS patients through a number 
of mechanisms including modification of gut mucosal barrier 
function, the luminal microbiome, the mucosal immune system, 
visceral sensation as well as alterations in fermentation and 
production of bacteriocins or substances with neurotransmit-
ter properties.
115 Though numerous RCTs have evaluated the 
efficacy of probiotics in IBS patients, most suffer from serious 
methodological flaws.
116 In a recent systematic review, Brenner 
and colleagues reported that of 16 RCTs evaluating probiotics 
in the treatment of IBS, Bifidobacterium infantis (B. infantis) 
35624 was the only one which provided significant improve-
ments in IBS symptoms in appropriately designed, albeit short Chey WD, et al: Pharmacologic and Complementary and Alternative Medicine Therapies for Irritable Bowel Syndrome  261
term, studies.
117 In the study by O’Mahoney et al., IBS patients 
were randomized to receive B. infantis 35624, Lactobacillus sali-
varius (L. salivarius) UCC4331, or placebo. Patients randomized 
to B. infantis 35624 experienced a greater reduction in symp-
tom scores for abdominal pain/discomfort, bloating/distention, 
and bowel movement difficulty compared to placebo. This study 
also reported normalization of peripheral blood mononuclear 
cell cytokine levels in IBS patients with B. infantis 35624 but 
not with L. salivarius UCC4331 suggesting a possible anti-
inflammatory effect.
118 The second study by Whorwell et al. was 
a dose-ranging study which found that B. infantis 35624 at a 
dose of 10
8 CFU/mL was significantly more likely than placebo 
to improve the primary outcome of abdominal pain/discomfort 
(p=0.023) as well as global IBS symptoms (p=0.028) and bowel 
habit satisfaction (p=0.014) at 4 weeks. The greatest benefits 
were observed in IBS-D patients. Somewhat surprisingly, a 
higher dose of B. infantis 35624 (10
10 CFU/mL) was no more 
effective than placebo though concerns have been raised over 
the bioavailability/formulation of this dose.
119 It is logical to hy-
pothesize that other single and multi-strain probiotics will offer 
benefits to the symptoms of IBS. Further, large, methodologi-
cally rigorous randomized, controlled trials will be necessary to 
clarify this important issue.
2. Herbal therapies
One of the most extensively studied herbal therapies for IBS 
is “Tong xie yao fang (TXYF).” A systematic review of 12 ran-
domized trials which included 1,125 IBS patients found that 
TXYF was more effective than control treatments (relative risk 
[RR], 1.35; 95% confidence interval [CI], 1.21 to 1.50; p<0.05).
120 
Unfortunately, the quality of the included studies was poor and 
as such, any conclusions drawn from this systematic review 
must be viewed with extreme caution. 
Peppermint oil is extracted from Mentha piperita Linnaeus 
plant which possesses Ca
++-channel blocking activity and thus, 
leads to smooth muscle relaxation.
121,122 Previous meta-analyses 
and systematic reviews which assessed the efficacy of pepper-
mint oil in IBS patients included small studies with significant 
methodological flaws.
123,124 These analyses found that pepper-
mint oil was more efficacious than placebo for the treatment 
of IBS (odds ratio [OR], 2.7; 95% CI, 1.56 to 4.76) but the poor 
quality of the included studies cast doubt on the validity of 
these results.
124 A meta-analysis by Ford et al. which included 
more recent, higher quality studies (three studies with 345 pa-
tients) reported that peppermint oil was less likely to be associ-
ated with persistent IBS symptoms than placebo (RR, 0.40; 95% 
CI, 0.29 to 0.55). No statistically significant heterogeneity was 
noted in this analysis (I
2=22.0%, p=0.28).
125 One study showed 
that peppermint oil improved generic quality of life using SF-36 
as well as IBS symptoms.
126
Traditional Chinese herbal therapies have been evaluated in 
IBS patients. In one of the higher quality studies, 116 patients 
were randomized to receive either a standardized traditional 
Chinese herbal formula, an herbal combination formulated 
for each individual IBS patient based on her/his specific IBS 
symptoms, or placebo which looked and smelled like the test 
preparations. After 16 weeks, patients receiving either of the 
herbal formulations reported significantly greater improvements 
in their symptoms than placebo (42% vs 16%, p<0.05).
127 A 
recent Cochrane review which assessed over 70 different herbal 
therapies for IBS identified 75 trials which enrolled almost 8,000 
participants. Only three of the trials were felt to be of high 
methodological quality. Over ninety percent of the trials were 
performed in China.
128 Another recent well designed, random-
ized trial found that St. John’s Wort was actually less likely 
than placebo to improve IBS symptoms.
129 This study should 
remind providers that all herbal therapies for IBS are not created 
equally and that further well designed, appropriately powered 
trials are needed.
3. Acupunture
Acupunture is a traditional CAM technique that has been 
practiced in many far Eastern countries for thousands of years. 
Some have speculated that acupuncture, through effects on mo-
tility, visceral sensation, and/or brain-gut interactions, might be 
beneficial for IBS. There have been at least 4 double blind, sham 
controlled trials which have assessed the efficacy of acupunc-
ture in IBS patients.
130-133 To date, none has provided compelling 
evidence that acupuncture is superior to sham acupuncture as 
a treatment for IBS. In one of the best designed trials by Lembo 
et al.,
133 230 IBS patients were randomized to 5 groups: waitlist 
control, acupuncture with limited interaction, acupuncture with 
augmented interaction, sham acupuncture with limited interac-
tion, and sham acupuncture with augmented interaction. There 
was no statistically significant difference in the proportion of 
responders receiving acupuncture versus sham acupuncture. 
Further, for the secondary endpoints, there were no differences 
in responder rates for adequate relief of IBS, IBS QOL, and IBS-
symptom severity scale. Interestingly, both the acupuncture 
and sham acupuncture led to a significantly greater proportion 
of responders for the primary and many of the secondary out-
comes as compared to the waitlist control group.
The explanations for these results remain unclear but pos-
sible explanations include confounding by inadequacies in 
power, study methodology, and a reliable sham acupuncture 
control. In addition, one wonders whether the benefits of real 
and sham acupuncture over “usual care” are the consequence 
of the interaction between the CAM provider and patient. At 
present, it is reasonable to conclude that the available evidence 
has not identified a clear clinical benefit of acupuncture over 
sham acupuncture. However, at least a third of patients who 
receive acupuncture will experience substantial benefit in their 
IBS symptoms with a very low likelihood of side effects when 
compared to continuing usual care.262  Gut and Liver, Vol. 5, No. 3, September 2011
SUMMARY
The heterogeneity of pathogenesis and clinical phenotypes 
provides an explanation for the marginal therapeutic gains of-
fered by treatments found to be more effective than placebo in 
clinical trials. Traditional therapies have focused on modulating 
motility/transit and visceral sensation. As our understanding of 
the pathogenesis of symptoms in IBS patients has improved, so 
too has the number of novel therapies being developed for IBS. 
The popularity of CAM therapies is rapidly increasing. Though 
some high quality trials have recently been published, further 
data on the efficacy and safety of CAM therapies is greatly 
needed. Ironically, the way forward for the treatment of IBS is 
likely to lie in our growing understanding of pathogenesis with 
the consequent development of reliable biomarkers which of-
fer predictive value in terms of the success of specific therapies. 
Until that time, it is unlikely that any therapy will address more 
than a subgroup of the total population of IBS sufferers. 
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